Desentum Overview
- Year Founded
-
2011
- Status
-
Private
- Employees
-
15
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$31.8M
- Investors
-
6
Desentum General Information
Description
Developer of a biopharmaceutical platform designed to create novel types of allergen immunotherapy products to fight allergies. The company's platform offers recombinant allergens that can be modified to suppress the histamine release during the desensitization process to safely and effectively treat allergies by reprogramming the immune system's response, enabling healthcare providers to significantly reduce the risk of adverse effects and the time required to treat allergies.
Contact Information
Website
www.desentum.fiCorporate Office
- Tekniikantie 14
- 02150 Espoo
- Finland
Corporate Office
- Tekniikantie 14
- 02150 Espoo
- Finland
Desentum Timeline
Desentum Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Later Stage VC | 12-Oct-2026 | $31.8M | Completed | Clinical Trials - Phase 2 | ||
| 9. Later Stage VC | Completed | Clinical Trials - Phase 2 | ||||
| 8. Later Stage VC | 20-Feb-2024 | Completed | Clinical Trials - Phase 2 | |||
| 7. Later Stage VC (Series A) | 21-Jan-2022 | Completed | Clinical Trials - General | |||
| 6. Secondary Transaction - Private | 01-Oct-2021 | Completed | Clinical Trials - General | |||
| 5. Later Stage VC (Series A) | 01-Nov-2019 | Completed | Clinical Trials - General | |||
| 4. Grant | 29-Oct-2018 | Completed | Clinical Trials - General | |||
| 3. Later Stage VC (Series A) | 29-Nov-2017 | Completed | Clinical Trials - General | |||
| 2. Later Stage VC (Series A) | 31-Dec-2016 | $1.99M | $7.18M | Completed | Clinical Trials - General | |
| 1. Seed Round | 12-Oct-2012 | $5.19M | $5.19M | Completed | Clinical Trials - General |
Desentum Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | ||||||||
| Series A | ||||||||
| Series A | 2,338,000 | $1.14 | $1.14 | 1x | $1.14 | 14.24% | ||
| Series B | 4,280,796 | $0.5 | $0.5 | 1x | $0.5 | 26.07% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Desentum Comparisons
Industry
Financing
Details
Desentum Competitors (3)
One of Desentum’s 3 competitors is Easily (Drug Discovery), a Formerly Angel backed company based in New York, NY.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Easily (Drug Discovery) | Formerly Angel backed | New York, NY | ||||
| Allergopharma España | Corporation | Madrid, Spain | ||||
| Paras Biopharmaceuticals Finland | Accelerator/Incubator Backed | Oulu, Finland |
Desentum Patents
Desentum Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2026525506-A | A low-allergen variant of ara h 2, a major peanut allergen. | Pending | 12-Jun-2023 | ||
| AU-2024305143-A1 | Hypoallergenic variants of major peanut allergen, ara h 2 | Pending | 12-Jun-2023 | ||
| EP-4724467-A1 | Hypoallergenic variants of major peanut allergen, ara h 2 | Pending | 12-Jun-2023 | ||
| WO-2024256749-A1 | Hypoallergenic variants of major peanut allergen, ara h 2 | Inactive | 12-Jun-2023 | ||
| AU-2023348392-A1 | Thermosensitive hydrogel composition | Pending | 26-Sep-2022 | A61K9/0024 |
Desentum Signals
Desentum Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Springvest | Growth/Expansion | Minority | ||
| Horizon 2020 | Government | |||
| Cascara Ventures | Venture Capital | Minority | ||
| STO-Rahoitus | Corporation | Minority | ||
| Voima Ventures | Venture Capital | Minority |
Desentum FAQs
-
When was Desentum founded?
Desentum was founded in 2011.
-
Where is Desentum headquartered?
Desentum is headquartered in Espoo, Finland.
-
What is the size of Desentum?
Desentum has 15 total employees.
-
What industry is Desentum in?
Desentum’s primary industry is Biotechnology.
-
Is Desentum a private or public company?
Desentum is a Private company.
-
What is Desentum’s current revenue?
The current revenue for Desentum is .
-
How much funding has Desentum raised over time?
Desentum has raised $71M.
-
Who are Desentum’s investors?
Springvest, Horizon 2020, Cascara Ventures, STO-Rahoitus, and Voima Ventures are 5 of 6 investors who have invested in Desentum.
-
Who are Desentum’s competitors?
Easily (Drug Discovery), Allergopharma España, and Paras Biopharmaceuticals Finland are competitors of Desentum.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process